Polyploid hepatocytes compensate whole-genome doubling by lengthening G1

What the work claims

The central claim is that the immediate cellular response to whole-genome doubling is conserved across naturally occurring and experimentally induced polyploid cells: both cell size and protein synthesis scale with ploidy in similar ways.¹ The deeper and more consequential claim is that the divergent fitness outcomes of polyploidy arise not from the doubling event itself but from how a cell type adapts its cell cycle. In human hepatocyte organoids, naturally polyploid binucleated hepatocytes substantially lengthen G1, allowing total protein production to scale with genome content. In contrast, experimentally tetraploidized retinal pigment epithelial cells fail to extend G1 and either arrest or progress with insufficient biosynthesis.

How it works

The authors compare three systems: the programmed polyploid intestine of C. elegans, naturally polyploid human hepatocytes in organoid culture, and near-diploid human RPE1 cells forced into tetraploidy with dihydrocytochalasin B. They use live imaging, calibrated flow cytometry, and O-propargyl-puromycin incorporation to measure cell volume and nascent protein synthesis across matched G1-phase cells.

In C. elegans, intestinal cells reach 64C ploidy through endomitosis and endoreplication. Reducing replication by degrading MCM-4 and MCM-7 with auxin drops ploidy from about 28C to 16C and proportionally reduces intestinal cell volume, while diploid body-wall muscle cells are unaffected. In human hepatocyte organoids, binucleated cells make up around 6% of the population and have a median volume 2.2-fold larger than mononucleated cells. Calibrated flow cytometry of FUCCI-labeled G1 hepatocytes shows 4N cells are 2.00 ± 0.08-fold larger than 2N cells, with more than 7,500 2N cells and more than 220 4N cells analyzed per replicate across four independent experiments.

Protein synthesis does not scale perfectly with ploidy. In hepatocyte organoids, OPP signal in 4N G1 cells is 1.52 ± 0.09-fold higher than in 2N cells, and imaging of binucleated cells shows only a 1.58-fold median increase. In induced RPE1 tetraploids, OPP incorporation is 1.64 ± 0.03-fold higher in 4N G1 cells than in 2N cells. Thus both natural and induced polyploid cells show sublinear translation scaling.

The critical difference is G1 duration. Live imaging of FUCCI hepatocytes reveals that binucleated hepatocytes spend significantly longer in G1 than mononucleated hepatocytes. Integrating translation rate over the extended G1 restores total protein production to a 2.13-fold increase, matching ploidy. The authors estimate that G1 lengthening accounts for about 39% of this compensation. In induced RPE1 tetraploids, G1 duration does not significantly increase, and 42% of binucleated cells fail to enter S phase within 20 hours of imaging. The same hepatocyte response is seen whether polyploidy arises naturally or is induced with dihydrocytochalasin B, indicating the adaptation is cell-type-specific rather than mode-of-polyploidization-specific.

Where a skeptic should push

The single most load-bearing assumption is that hepatocyte organoids faithfully model the cell-cycle behavior of primary human hepatocytes. Fetal-derived hepatocyte organoids are a powerful system, but they are cultured in defined medium on basement-membrane extract, lack portal and central zonation cues, and may differ from adult hepatocytes in ploidy distribution and metabolic state. The finding that naturally and induced polyploid hepatocytes behave similarly within the organoid is internally consistent, but it does not prove the same G1 compensation occurs in the intact liver.

Second, the number of binucleated hepatocytes is small. Around 6% of dissociated organoid cells are 4N, and the live-imaging G1-duration comparison uses 50 binucleated nuclei versus 81 mononucleated nuclei across four experiments. The effect is statistically significant, but the sample is a minority population. Whether the same mechanism operates in highly polyploid adult hepatocytes with much higher ploidy remains open.

Third, the comparison with RPE1 cells is instructive but not a clean cell-type-versus-induction experiment. RPE1 cells are an untransformed epithelial line that normally remains diploid, while hepatocytes are a differentiated, post-mitotic-adjacent cell type programmed for polyploidy. The difference in G1 response could reflect lineage-specific cell-cycle wiring rather than a universal principle of natural versus induced polyploidy. A stronger test would induce polyploidy in a cell type that normally becomes polyploid, such as a megakaryocyte model, and ask whether it lengthens G1.

Fourth, OPP incorporation measures translation rate, not functional protein abundance or activity. A cell could translate more total protein but fail to produce the specific replication factors needed in the correct stoichiometry. The integration of OPP over G1 is a reasonable estimate of cumulative biosynthesis, but it is still an estimate based on a proxy.

Polyploid compensation as a liver-organoid design rule

For organoid models of human organs and the drug-discovery work built on them, the opportunity is to make ploidy and cell-cycle state explicit variables in liver organoid engineering. Hepatocyte ploidy is not a neutral background property; it affects cell size, translation, and G1 duration. Drug screens that assume all hepatocytes in an organoid are equivalent could miss ploidy-dependent effects, especially for compounds that target cell-cycle entry, DNA replication, or biosynthetic pathways. Regenerative-medicine efforts that expand hepatocyte organoids for transplantation may also need to track ploidy, because a culture that enriches diploid cells could differ in replication capacity and metabolic output from one that enriches polyploid cells.

The non-obvious implication is that polyploidy may be a feature, not a bug, in liver organoid maturation. In vivo, adult human hepatocytes are predominantly polyploid, and polyploidy has been linked to protective functions against DNA damage and metabolic stress. If hepatocyte organoids are intentionally matured toward a polyploid state, the G1-lengthening compensation described here becomes a design constraint: the culture must allow enough time for biosynthetic accumulation before S phase. Protocols that push rapid cycling might produce diploid or poorly compensated polyploid hepatocytes that do not represent the adult liver well.

The genuine threat is extrapolation to cancer. Whole-genome doubling is common in tumors and is associated with chromosomal instability and poor prognosis. The paper shows that unscheduled polyploidy in RPE1 cells is harmful because G1 is not extended, but cancer cells can evolve compensatory mechanisms. A hepatoma model might use the same G1-lengthening trick, or it might use a different one. Liver organoid cancer models will need to distinguish these routes, because a drug that blocks G1 lengthening in a benign polyploid hepatocyte might push a tetraploid cancer cell toward arrest or aneuploidy rather than death.

Another threat is oversimplification of the size-ploidy relationship. Cell volume depends on cell age, medium composition, and matrix mechanics, not only DNA content. In hepatocyte organoids, the authors gate on G1 cells and control for cell-cycle position, but most organoid assays do not. A screen that reports cell size or proliferation without ploidy information may be confounded by an unmeasured polyploid fraction. For drug discovery, the practical takeaway is to include ploidy and cell-cycle reporters in liver organoid characterization, particularly when the readout is growth, metabolism, or genotoxicity.

The bottom line

Established: in human hepatocyte organoids, naturally polyploid hepatocytes scale cell volume linearly with ploidy, show sublinear scaling of protein synthesis, and compensate by lengthening G1 so that total protein production matches genome content. Experimentally induced tetraploid RPE1 cells scale size and translation similarly but fail to extend G1 and show reduced fitness. Hypothesis: that cell-type-specific cell-cycle adaptation, not whole-genome doubling per se, determines whether polyploidy is tolerated. What would confirm the case is direct measurement of the same compensation in adult human liver tissue and in additional naturally polyploid cell types. What would break the case is finding that organoid culture conditions artificially induce the G1 extension, or that cancer cells bypass the requirement through unrelated mechanisms. The work reframes polyploidy from a passive scaling phenomenon to an active cell-cycle decision, with direct relevance to how liver organoids are built and interpreted.